Related Experiment Video
Updated: Jul 17, 2025
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
Published on: March 14, 2020
Granulocyte-colony stimulating factor in decompensated liver cirrhosis: a meta-analysis of four randomized controlled
Reem Dimachkie1, Rachelle Hamadi1, Zakaria Alameddine1
1Internal medicine department, Staten Island University Hospital.
Insights
Granulocyte-colony stimulating factor (GCSF) combined with standard medical therapy (SMT) may improve survival rates for patients with decompensated cirrhosis. This GCSF therapy also showed benefits in liver function scores.
Area of Science:
- Hepatology
- Immunology
- Regenerative Medicine
Background:
- Decompensated cirrhosis (DC) presents high mortality with limited liver transplant options.
- Granulocyte-colony stimulating factor (GCSF) offers regenerative and immunomodulatory potential for liver disease.
- The efficacy of GCSF in DC remains controversial, necessitating rigorous evaluation.
Approach:
- A meta-analysis of randomized controlled trials (RCTs) was conducted.
- Four RCTs involving 595 patients with decompensated cirrhosis were analyzed.
- The study compared GCSF plus standard medical therapy (SMT) against SMT alone.
Key Points:
- GCSF + SMT demonstrated higher odds of survival compared to SMT alone (RR 1.28, 95% CI 1.08-1.5).
- Patients receiving GCSF showed improved Child-Pugh-Turcotte scores, indicating better liver function.
- While not significant, MELD scores did not show improvement, and heterogeneity was noted among studies.
Conclusions:
- GCSF in combination with SMT shows promise for improving survival and liver function in decompensated cirrhosis patients.
- GCSF may be a beneficial therapeutic option for end-stage liver disease.
- Further RCTs are warranted to confirm these findings and elucidate GCSF's role.
Background:
Decompensated liver cirrhosis (DC) has high mortality, but liver transplantation is limited due to organ scarcity and contraindications for transplantation. Granulocyte-colony stimulating factor (GCSF) shows potential for liver disease treatment with its regenerative and immunomodulatory properties. To assess the controversial use of GCSF in DC, a meta-analysis of randomized controlled trials (RCTs) compared survival benefits in patients receiving GCSF plus standard medical therapy (SMT) versus SMT alone.
Methods:
A literature search was performed in four databases from data inception up to December 2022, and all registered randomized controlled (RCTs) evaluating GCSF-based therapies for cirrhotic patients were included.
Results:
A study combining four RCTs assessed the impact of GCSF with SMT in 595 patients with decompensated cirrhosis. The results indicated that GCSF + SMT led to higher odds of survival compared to SMT alone [risk ratio 1.28, 95% CI (1.08-1.5)]. Heterogeneity existed among the studies, but overall, GCSF showed potential in improving survival. The intervention group exhibited improved Child-Pugh-Turcotte scores [-2.51, CI (-4.33 to -0.70)], and increased CD34 levels, but no significant improvement in MELD scores. These findings suggest GCSF may benefit patients with decompensated cirrhosis in terms of survival and liver function.
Conclusion:
These results suggest that the combination of GCSF and SMT may have a positive impact on the survival rate and improvement in CPT score in patients with DC. Further RCTs are needed to shed more light on this promising modality in end-stage liver disease.
Related Concept Videos
01:01Regulation of Hematopoietic Stem Cells
01:15Differentiation of Common Myeloid Progenitor Cells
01:24Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...